At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
Anastrozole +1 moredrug
Likely dose
Anastrozole 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose, Comparative Bioavailability Study of Two Formulations of Anastrozole 1 mg Tablets Under Fed Conditions
In Brief
A Phase 1 clinical trial evaluating Anastrozole for Healthy. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the comparative bioavailability between Anastrozole 1 mg Tablets (Teva Pharmaceuticals, USA) and Arimidex® 1 mg Tablets (AstraZeneca Pharmaceuticals LP, USA), after a single-dose in healthy subjects under fed conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
Primary CompletionOct 2005
First PostedAug 2010
TodayJul 2026
First PostedAug 17, 2010
Enrollment StartSep 1, 2005
Primary CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.9 years ago
Interventions
Anastrozoledrug
1 mg Tablets
Anastrozoledrug
1 mg Tablets